TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05846711

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BPPV diagnostic
Description: Supine Roll Test and Dix-Hallpike Test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BPPV diagnostic
Description: Supine Roll Test and Dix-Hallpike Test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRV chair
Description: Mechanical rotational chair

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VNG goggles
Description: Goggles for video nystagmography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VNG goggles
Description: Goggles for video nystagmography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IMU sensor
Description: A sensor that measures triaxial acceleration and triaxial angular velocity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual BPPV diagnostics
Description: Bedside BPPV diagnostics
Study: NCT05597397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RLRL
Description: In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
Study: NCT06145646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle warm-up
Description: Passive heating of the vastus lateralis of the right quadriceps will be performed using a microwave device. The device will be set at a power of 150 W and a distance of 10-15 cm from the skin surface for 20 minutes with the purpose of increasing local muscle temperature to 40 ºC.
Study: NCT05505500

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Concept Elicitation Interviews are used to create tools followed by Cognitive Debrief Interviews that are used to review created tools.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Concept Elicitation Interviews are used to create tools followed by Cognitive Debrief Interviews that are used to review created tools.
Study: NCT06502418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Description: 7 acupuncture points will be used to managed pain and improved patient's experience
Study: NCT06551922

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Instrumental Soft Tissue Mobilization Technique with Conservative Treatment
Description: TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes will be positioned.~Frequency: 3 times per week. Duration: 90 seconds- 2 minutes on each muscle (Purbia, 2023). Technique: A therapist uses Ergon tools to apply gentle pressure and strokes along the targeted muscles and fascial tissues. Different IASTM techniques, like stroking, raking, and hooking, address specific tissue restrictions. The therapist should continue the IASTM technique for 5-10 minutes, or until the stiffness in the knee is reduced (Mubashar et al., 2022; Purbia, 2023).~Conservative Treatment: Stretching exercises for the hamstrings and quadriceps to improve flexibility and reduce tension. Affected iliotibialband. Hold for 30 seconds. Uncross your legs and stand up straight again. Repeat four more times (Mubashar et al., 2022).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conservative Treatment
Description: TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes will be positioned.~Stretching exercises with hold for 30 seconds. Uncross your legs and stand up straight again (Mubashar et al., 2022).~Quadriceps Strengthening: Perform exercises like straight leg raises, seated leg press and squats to strengthen (Lim \& Al-Dadah, 2022).~Hamstring Strengthening: Include exercises like leg curls to strengthen the hamstring muscles (Lim \& Al-Dadah, 2022).~Calf Strengthening: Perform calf raises to strengthen the calf muscles (Lim \& Al-Dadah, 2022).~Balance Exercises: Incorporate balance exercises like single-leg stands on a foam pad (Lim \& Al-Dadah, 2022).~Ice Therapy: Apply ice packs to the affected knee for 15-20 minutes (Lim \& Al-Dadah, 2022).
Study: NCT06325631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular injection to lumbar facet joint
Description: to treat low back pain caused by facet joint syndrome

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular injection to lumbar facet joint
Description: to treat low back pain caused by facet joint syndrome

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular injection to lumbar facet joint
Description: to treat low back pain caused by facet joint syndrome
Study: NCT06337032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF (High Dose Tablet)
Description: 200/25 mg fixed-dose combination (FDC) tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF (High Dose Tablet)
Description: 200/25 mg fixed-dose combination (FDC) tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF (Low Dose Tablet)
Description: 200/10 mg FDC tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF (Lowest Dose Tablet)
Description: 120/15 mg FDC tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF (Lowest Dose Tablet)
Description: 120/15 mg FDC tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF (High Dose TOS)
Description: 60/7.5 mg tablet for oral suspension (TOS) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF (Low Dose TOS)
Description: 30/3.75 mg TOS administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF (Lowest Dose TOS)
Description: 15/1.88 mg TOS administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF (Low Dose)
Description: 90/90/120/6 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat (High Dose)
Description: 150 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat (Low Dose)
Description: 90 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat (TOS)
Description: 30 mg TOS administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (High Dose)
Description: 50/200/25 mg FDC tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (High Dose)
Description: 50/200/25 mg FDC tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (High Dose)
Description: 50/200/25 mg FDC tablet administered orally
Study: NCT04340531

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive referred to counseling session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Cessation Counseling
Description: Receive referred to counseling session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive phone counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Cessation Counseling
Description: Receive phone counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Undergo training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Undergo training
Study: NCT06110286

Intervention type: OTHER
Intervention: Photorefractive keratectomy
Description: Laser keratectomy by EX500 excimer laser after removal of corneal epithelium either mannually or by laser ablation

Intervention type: OTHER
Intervention: Photorefractive keratectomy
Description: Laser keratectomy by EX500 excimer laser after removal of corneal epithelium either mannually or by laser ablation
Study: NCT05099510

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NatrunixTM
Description: The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha). The entire XB2001 heavy and light chain sequences are identical to those found in naturally-occurring human IgG4-kappa, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control for NatrunixTM subcutaneous injection.
Study: NCT05098132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-012
Description: pegylated alpha/beta-biased engineered interleukin-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-012
Description: pegylated alpha/beta-biased engineered interleukin-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-012
Description: pegylated alpha/beta-biased engineered interleukin-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-012
Description: pegylated alpha/beta-biased engineered interleukin-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-012
Description: pegylated alpha/beta-biased engineered interleukin-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-012
Description: pegylated alpha/beta-biased engineered interleukin-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: anti-PD-1 humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: anti-PD-1 humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: anti-PD-1 humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: anti-PD-1 humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: antifolate chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: antifolate chemotherapy
Study: NCT05143541

Intervention type: DEVICE
Intervention: AEON Endostapler
Description: Surgery with AEON Endostapler
Study: NCT06180291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRECOP program
Description: PRECOP program is the first program combining early detection of cerebral palsy with implementation of early interventions following the latest international recommendations (multidisciplinary program at home, with the possibility of intensive courses, coaching parental, in the first 2 years of life).~This comprehensive monitoring is implemented as soon as the infant arrives at home, by a multidisciplinary team and continues during the child's first 2 years. It includes:~* Follow-up organized primarily at home~* Monitoring of psychomotor development~* Screening for possible cerebral palsy~* Comprehensive support for the child's development: weight, diet, sleep...~* Reeducation, implementation of SMART type objectives (Specific, Measurable, Achievable, Achievable, Timely defined) determined with parents~* Creation of equipment if necessary: early seating installation in particular~* Parental support and guidance for optimizing early care~* Parental psychological support.
Study: NCT06438939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy for diagnostical purposes
Description: Incisional biopsy is the current golden standard for OPMD/OSCC diagnosis. Yet, the site it shall be performed is choosen by clinician at naked eyes. We will compare and study the results of performing the common golden standard biopsy site when guided by NBI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy for diagnostical purposes
Description: Incisional biopsy is the current golden standard for OPMD/OSCC diagnosis. Yet, the site it shall be performed is choosen by clinician at naked eyes. We will compare and study the results of performing the common golden standard biopsy site when guided by NBI.
Study: NCT06134505

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of Barrier cream group 1 in the healing of diaper dermatitis
Description: In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that Barrier cream 1 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved.
Study: NCT05329532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modi-1/Modi-1v
Description: Modi-1/Modi-1v administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modi-1/Modi-1v
Description: Modi-1/Modi-1v administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modi-1/Modi-1v
Description: Modi-1/Modi-1v administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet600™ microneedle device (NanoPass)
Description: Intradermal injection device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet600™ microneedle device (NanoPass)
Description: Intradermal injection device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet600™ microneedle device (NanoPass)
Description: Intradermal injection device
Study: NCT06248060

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preanaesthetic classical physical consultation
Description: Pre-anaesthetic classical consultation before teleconsultation implementation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preanaesthetic teleconsultation
Description: Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
Study: NCT04928443

Intervention type: OTHER
Intervention: Scar dressing group
Description: Patients treated with scar dressing for surgical scar care are invited to participate this study and allocated in scar dressing group despite the length of caring period.

Intervention type: OTHER
Intervention: Regular care group
Description: Patients receiving regular scar care are retrospectively identified with matching factors, such as gender, age, length of surgical wound and surgical procedure.
Study: NCT04746222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral capsule faecal microbiota transplantation
Description: Single dose of 30 oral capsules containing healthy donor stool from a stool bank

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 30 oral placebo capsules
Study: NCT06337032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (High Dose)
Description: 50/200/25 mg FDC tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose)
Description: 30/120/15 mg FDC tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF (Low Dose)
Description: 30/120/15 mg FDC tablet administered orally
Study: NCT05648578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki attempt
Description: Four reiki sessions were applied twice a week, on the same days of the week, lasting 25-35 minutes each.
Study: NCT05332730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2506 injection
Description: 50 mg, subcutaneous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simponi® (EU commercially available product)
Description: 50 mg, subcutaneous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simponi® (US commercially available product)
Description: 50 mg, subcutaneous administration
Study: NCT04930822

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Table Top Visual Intervention
Description: Table top visual interventions and exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioness Integrated Therapy System Visual Intervention
Description: Digital visual interventions and exercises.
Study: NCT05538533

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 46 Gy Radiation Therapy
Description: Dose per fraction of 4.6.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 40 Gy Radiation Therapy
Description: Dose per fraction 5.7.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 35 Gy Radiation Therapy
Description: Dose per fraction 7.0.
Study: NCT05806086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panfoshu+Conventional Treatment（program-A）
Description: On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panfoshu+Conventional Treatment（program-B）
Description: On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Treatment
Description: Patients in this group were treated with only the conventional treatment.
Study: NCT05357638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: 8 weeks of HIIT, 2x/week for about 30 minutes/session on a cycle ergometer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Description: 8 weeks of CAT, 2x/week for about 50 minutes/session on a cycle ergometer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement Advice
Description: Weekly step goal, monitored using an activity tracker, +3000 steps/day for 5 days/week, step goal is based on average step count in the 4 weeks of baseline prior to the intervention
Study: NCT06319131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Using the transjugular approach, TIPS was created under local anesthesia. The first branch of the left or right portal vein (PV) was punctured by RUPS-100 set guided by digital subtraction angiography. After successful access into PV, direct portography was performed and all visible varices and/or concurrent spontaneous portosystemic shunts (SPSS) were embolized with coils and n-butyl cyanoacrylate. A polytetrafluoroethylene-covered stent (Viatorr Endoprosthesis, GORE and Associates, Flagstaff, Arizona, USA) with a diameter of 8 mm was implanted and fully dilated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin
Description: Nadroparin calcium will be subcutaneously injected with the dose of 85IU/kg q12h
Study: NCT03938467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiseptic Cleanser
Description: Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation. The mechanical action of the Irrisept system removes bacteria and debris without harming underlying tissues. Irrisept has demonstrated broad spectrum bactericidal activity against antibiotic-resistant strains. Its contents are wrapped in two sequential sterilization wraps which repel water blood, and saline, making it effective against both air and water borne bacteria.
Study: NCT05194657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enhanced depth of focus IOL
Description: Acrysof IQ Vivity, enhanced depth of focus IOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monofocal IOL
Description: Acrysof IQ, monofocal IOL
Study: NCT06134505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Barrier cream 2 in the healing of diaper dermatitis
Description: In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that barrier cream 2 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved.
Study: NCT05119673

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bi-plane sonographic view to difficult peripheral vascular access using Butterfly iQ+®
Description: Bi-plane Butterfly iQ+® sonographic visualization will be used to help Emergency Department operators to get a venous peripheral access in a population of patients considered difficult for this task based on their history or the present clinical situation.
Study: NCT05534529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin Acetate
Description: This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.